Patents by Inventor John P. Adelman
John P. Adelman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200291383Abstract: Compositions and methods for editing endogenous RNA molecules are provided.Type: ApplicationFiled: October 9, 2018Publication date: September 17, 2020Inventors: Gail MANDEL, John P. ADELMAN, John SINNAMON
-
Publication number: 20120088255Abstract: There is disclosed a pharmaceutical composition for treating solid tumors that overexpress HER-2, comprising an agent selected from the group consisting of (a) an isolated polypeptide having from about 50 to 79 amino acids taken from the sequence of SEQ ID NO:1, wherein the polypeptide binds to the extracellular domain ECD of HER-2 at an affinity of at least 108, (b) an isolated and glycosylated polypeptide having from about 300 to 419 amino acids taken from the sequence of SEQ ID NO:2, wherein the C terminal 79 amino acids are present, and wherein at least three N-linked glycosylation sites are present, (c) a monoclonal antibody that binds to the ECD of HER-2, and (d) combinations thereof, with the proviso that the agent cannot be the monoclonal antibody alone, and pharmaceutically acceptable carrier.Type: ApplicationFiled: May 9, 2011Publication date: April 12, 2012Applicant: Oregon Health & Science UniversityInventors: Joni K. Doherty, Gail M. Clinton, John P. Adelman
-
Patent number: 7939080Abstract: There is disclosed a pharmaceutical composition for treating solid tumors that overexpress HER-2, comprising an agent selected from the group consisting of (a) an isolated polypeptide having from about 50 to 79 amino acids taken from the sequence of SEQ ID NO:1, wherein the polypeptide binds to the extracellular domain ECD of HER-2 at an affinity of at least 108, (b) an isolated and glycosylated polypeptide having from about 300 to 419 amino acids taken from the sequence of SEQ ID NO:2, wherein the C terminal 79 amino acids are present, and wherein at least three N-linked glycosylation sites are present, (c) a monoclonal antibody that binds to the ECD of HER-2, and (d) combinations thereof, with the proviso that the agent cannot be the monoclonal antibody alone, and pharmaceutically acceptable carrier.Type: GrantFiled: June 30, 2008Date of Patent: May 10, 2011Assignee: Oregon Health & Science UniversityInventors: Joni K. Doherty, Gail M. Clinton, John P. Adelman
-
Publication number: 20090270316Abstract: There is disclosed a pharmaceutical composition for treating solid tumors that overexpress HER-2, comprising an agent selected from the group consisting of (a) an isolated polypeptide having from about 50 to 79 amino acids taken from the sequence of SEQ ID NO:1, wherein the polypeptide binds to the extracellular domain ECD of HER-2 at an affinity of at least 108, (b) an isolated and glycosylated polypeptide having from about 300 to 419 amino acids taken from the sequence of SEQ ID NO:2, wherein the C terminal 79 amino acids are present, and wherein at least three N-linked glycosylation sites are present, (c) a monoclonal antibody that binds to the ECD of HER-2, and (d) combinations thereof, with the proviso that the agent cannot be the monoclonal antibody alone, and pharmaceutically acceptable carrier.Type: ApplicationFiled: June 30, 2008Publication date: October 29, 2009Applicant: Oregon Health & Science UniversityInventors: Joni K. Doherty, Gail M. Clinton, John P. Adelman
-
Patent number: 7534869Abstract: This invention relates to small and intermediate conductance, calcium-activated potassium channel proteins. More specifically, the invention relates to compositions and methods for making and detecting calcium-activated potassium channel proteins and the nucleic acids encoding calcium-activated potassium channel proteins. The invention also provides methods and compositions for assaying compounds which increase or decrease potassium ion flux through a calcium-activated potassium channel.Type: GrantFiled: April 27, 2005Date of Patent: May 19, 2009Assignee: Icagen, Inc.Inventors: John P. Adelman, James Maylie, Chris T. Bond, Christopher P. Silvia
-
Patent number: 7393823Abstract: There is disclosed a pharmaceutical composition for treating solid tumors that overexpress HER-2, comprising an agent selected from the group consisting of (a) an isolated polypeptide having from about 50 to 79 amino acids taken from the sequence of SEQ ID NO. 1, wherein the polypeptide binds to the extracellular domain ECD of HER-2 with an affinity binding constant of at least 108 M?1, (b) an isolated and glycosylated polypeptide having from about 300 to 419 amino acids taken from the sequence of SEQ ID NO. 2, wherein the C terminal 79 amino acids are present, and wherein at least three N-linked glycosylation sites are present, (c) a monoclonal antibody that binds to the ECD of HER-2, and (d) combinations thereof, with the proviso that the agent cannot be the monoclonal antibody alone, and a pharmaceutically acceptable carrier.Type: GrantFiled: January 20, 1999Date of Patent: July 1, 2008Assignee: Oregon Health and Science UniversityInventors: Joni Kristin Doherty, Gail M. Clinton, John P. Adelman
-
Patent number: 7026451Abstract: This invention relates to small and intermediate conductance, calcium-activated potassium channel proteins. More specifically the invention relates to compositions and methods for making and detecting calcium-activated potassium channel proteins and the nucleic acids encoding calcium-activated potassium channel proteins. The invention also provides methods and compositons for assaying compounds which increase or decrease potassium ion flux through a calcium-activated potassium channel.Type: GrantFiled: April 3, 2002Date of Patent: April 11, 2006Assignees: Icagen, Incorporated, Oregon Health Sciences UniversityInventors: John P. Adelman, James Maylie, Chris T. Bond, Christopher P. Silvia
-
Patent number: 6987169Abstract: This invention relates to small and intermediate conductance, calcium-activated potassium channel proteins. More specifically, the invention relates to compositions and methods for making and detecting calcium-activated potassium channel proteins and the nucleic acids encoding calcium-activated potassium channel proteins. The invention also provides methods and compositions for assaying compounds which increase or decrease potassium ion flux through a calcium-activated potassium channel.Type: GrantFiled: April 3, 2002Date of Patent: January 17, 2006Assignees: Oregon Health Sciences University, Icagen, Inc.Inventors: John P. Adelman, James Maylie, Chris T. Bond, Christopher P. Silvia
-
Patent number: 6894147Abstract: This invention relates to small and intermediate conductance, calcium-activated potassium channel proteins. More specifically, the invention relates to compositions and methods for making and detecting calcium-activated potassium channel proteins and the nucleic acids encoding calcium-activated potassium channel proteins. The invention also provides methods and compositions for assaying compounds which increase or decrease potassium ion flux though a calcium-activated potassium channel.Type: GrantFiled: April 3, 2002Date of Patent: May 17, 2005Assignees: Oregon Health Sciences University, Icagen, Inc.Inventors: John P. Adelman, James Maylie, Chris T. Bond, Christopher P. Silvia
-
Patent number: 6828420Abstract: This invention relates to small and intermediate conductance, calcium-activated potassium channel proteins. More specifically, the invention relates to compositions and methods for making and detecting calcium-activated potassium channel proteins and the nucleic acids encoding calcium-activated potassium channel proteins. The invention also provides methods and compositions for assaying compounds which increase or decrease potassium ion flux through a calcium-activated potassium channel.Type: GrantFiled: April 3, 2002Date of Patent: December 7, 2004Assignees: Oregon Health Sciences University, Icagen, Inc.Inventors: John P. Adelman, James Maylie, Chris T. Bond, Christopher P. Silvia
-
Patent number: 6828122Abstract: This invention relates to small and intermediate conductance, calcium-activated potassium channel proteins. More specifically, the invention relates to compositions and methods for making and detecting calcium-activated potassium channel proteins and the nucleic acids encoding calcium-activated potassium channel proteins. The invention also provides methods and compositions for assaying compounds which increase or decrease potassium ion flux through a calcium-activated potassium channel.Type: GrantFiled: April 2, 2002Date of Patent: December 7, 2004Assignees: Oregon Health Sciences University, Icagen, Inc.Inventors: John P. Adelman, James Maylie, Chris T. Bond, Christopher P. Silvia
-
Patent number: 6828123Abstract: This invention relates to small and intermediate conductance, calcium-activated potassium channel proteins. More specifically, the invention relates to compositions and methods for making and detecting calcium-activated potassium channel proteins and the nucleic acids encoding calcium-activated potassium channel proteins. The invention also provides methods and compositions for assaying compounds which increase or decrease potassium ion flux through a calcium-activated potassium channel.Type: GrantFiled: April 3, 2002Date of Patent: December 7, 2004Assignees: Oregon Health Sciences University, Icagen, Inc.Inventors: John P. Adelman, James Maylie, Chris T. Bond, Christopher P. Silvia
-
Patent number: 6797486Abstract: This invention relates to small and intermediate conductance, calcium-activated potassium channel proteins. More specifically, the invention relates to compositions and methods for making and detecting calcium-activated potassium channel proteins and the nucleic acids encoding calcium-activated potassium channel proteins. The invention also provides methods and compositions for assaying compounds which increase or decrease potassium ion flux through a calcium-activated potassium channel.Type: GrantFiled: May 24, 1999Date of Patent: September 28, 2004Assignees: ICAgen, Incorporated, Oregon Health Sciences UniversityInventors: John P. Adelman, James Maylie, Chris T. Bond, Christopher P. Silvia
-
Patent number: 6692937Abstract: This invention relates to small and intermediate conductance, calcium-activated potassium channel proteins. More specifically, the invention relates to compositions and methods for making and detecting calcium-activated potassium channel proteins and the nucleic acids encoding calcium-activated potassium channel proteins. The invention also provides methods and compositions for assaying compounds which increase or decrease potassium ion flux through a calcium-activated potassium channel.Type: GrantFiled: August 3, 2001Date of Patent: February 17, 2004Assignees: ICAgen, Incorporated, Oregon Health Sciences UniversityInventors: John P. Adelman, James Maylie, Chris T. Bond, Christopher P. Silvia
-
Publication number: 20040022785Abstract: An alternative HER-2/neu product, herstatin, consists of subdomains I and II from the ectodomain of p185HER-2 and a unique 79 amino acid C-terminus encoded by intron 8. Recombinant herstatin added to cells was found to bind to and inhibit p185HER-2. The effects of ectopic expression of herstatin in combination with either p185HER-2 or with its homolog, the EGF receptor, in several cell lines was studied. Cotransfection of herstatin with HER-2 inhibited p185HER-2 levels and caused an approximate 8-fold reduction in p185 tyrosine phosphorylation. Inhibition ofp185HER-2 tyrosine phosphorylation corresponded to a dramatic decline in colony formation by cells that coexpressed p185HER-2 and herstatin. Herstatin also interferred with EGF activation of the EGF receptor in cotransfected cells as demonstrated by impaired receptor tyrosine phosphorylation, reduced receptor down-regulation, and growth suppression.Type: ApplicationFiled: November 22, 2002Publication date: February 5, 2004Inventors: Gail M. Clinton, Joni Kristin Doherty, John P. Adelman
-
Publication number: 20030105284Abstract: This invention relates to small and intermediate conductance, calciumactivated potassium channel proteins. More specifically the invention relates to compositions and methods ror making and detecting calciumactivated potassium channel proteins and the nucleic acids encoding calciumactivated potassium channel proteins.Type: ApplicationFiled: April 3, 2002Publication date: June 5, 2003Applicant: Oregon Health Sciences UniversityInventors: John P. Adelman, James Maylie, Chris T. Bond, Christopher P. Silvia
-
Publication number: 20030082684Abstract: This invention relates to small and intermediate conductance, calcium-activated potassium channel proteins. More specifically, the invention relates to compositions and methods for making and detecting calcium-activated potassium channel proteins and the nucleic acids encoding calcium-activated potassium channel proteins. The invention also provides methods and compositions for assaying compounds which increase or decrease potassium ion flux through a calcium-activated potassium channel.Type: ApplicationFiled: April 3, 2002Publication date: May 1, 2003Applicant: Oregon Health Sciences UniversityInventors: John P. Adelman, James Maylie, Chris T. Bond, Christopher P. Silvia
-
Publication number: 20030082683Abstract: This invention relates to small and intermediate conductance, calcium-activated potassium channel proteins. More specifically, the invention relates to compositions and methods for making and detecting calcium-activated potassium channel proteins and the nucleic acids encoding calcium-activated potassium channel proteins. The invention also provides methods and compositions for assaying compounds which increase or decrease potassium ion flux through a calcium-activated potassium channel.Type: ApplicationFiled: April 2, 2002Publication date: May 1, 2003Applicant: Oregon Health Sciences UniversityInventors: John P. Adelman, James Maylie, Chris T. Bond, Christopher P. Silvia
-
Publication number: 20030044910Abstract: This invention relates to small and intermediate conductance, calcium-acaivated potassium channel proteins. More specifically, the invention relates to compositions and methods for making and detecting calcium-activated potassium channel proteins and the nucleic acids encoding calcium-activated potassium channel proteins. The invention also provides methods and compositons for assaying compounds which increase or decrease potassium ion flux through a calcium-activated potassium channel.Type: ApplicationFiled: April 3, 2002Publication date: March 6, 2003Applicant: Oregon Health Sciences UniversityInventors: John P. Adelman, James Maylie, Chris T. Bond, Christopher P. Silvia
-
Publication number: 20030040048Abstract: This invention relates to small and intermediate conductance, calcium-activated potassium channel proteins. More specifically, the invention relates to compositions and methods for making and detecting calcium-activated potassium channel proteins and the nucleic acids encoding calcium-activated potassium channel proteins. The invention also provides methods and compositons for assaying compounds which increase or decrease potassium ion flux through a calcium-activated potassium channel.Type: ApplicationFiled: April 3, 2002Publication date: February 27, 2003Applicant: Oregon Health Sciences UniversityInventors: John P. Adelman, James Maylie, Chris T. Bond, Christopher W. Silvia